Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 7,277 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Ramy Riad Ahmed Ibrahim sold 7,277 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $124,436.70. Following the transaction, the insider directly owned 102,588 shares of the company’s stock, valued at approximately $1,754,254.80. This trade represents a 6.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

NYSE:TAK traded down $0.06 during trading hours on Wednesday, reaching $17.42. 2,004,364 shares of the company traded hands, compared to its average volume of 4,402,927. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $16.49 and its two-hundred day moving average price is $17.13. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The stock has a market capitalization of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion for the quarter. Analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

TAK has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA raised its stake in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after buying an additional 1,684 shares during the last quarter. SHP Wealth Management bought a new stake in shares of Takeda Pharmaceutical in the fourth quarter worth $42,000. Caitong International Asset Management Co. Ltd increased its position in Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.